← Back to all trials
Active Not Recruiting
NCT06809595
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Conditions: Generalized Anxiety Disorder
Sex: All
Ages: 18 Years – 74 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 245
Sponsor: Definium Therapeutics US, Inc.
Location: Preferred Research Partners, Inc. Little Rock Arkansas
Summary
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis of GAD per DSM-5
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20
Exclusion Criteria:
1. Certain psychiatric disorders (other than generalized anxiety disorder)
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness
Source: ClinicalTrials.gov (NCT06809595). StuddyBuddy aggregates publicly available trial information.
